Skip to main content
. 2020 Jan 10;69(3):435–448. doi: 10.1007/s00262-019-02472-z

Fig. 2.

Fig. 2

Percentages of Mo-MDSCs in patients divided by clinicopathological features. CD14+HLA-DRlow/− Mo-MDSCs in peripheral blood was assessed by flow cytometry and stratified according to clinicopathological features (see Table 1). Median percentage of Mo-MDSCs as divided by (a) metastatic site or (b) according to de novo or distant recurrent MBC. Error bars; SEM. Exact P values, by Mann–Whitney Wilcoxon, are indicated